Instrumento Inactivo

Otros idiomas Capricor Therapeutics Inc Nasdaq

Acciones

US14070B1017

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	09/05
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting	09/05
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences	08/05
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13	06/05
Capricor Therapeutics Gets Another Type-B Meeting With FDA for Duchenne Muscular Dystrophy Investigational Drug	24/04
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24/04
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	24/04
Capricor Therapeutics to Present at Upcoming Investor Conferences	21/03
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	06/03
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference	06/03
Capricor: Q4 Earnings Snapshot	29/02
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q4 Revenue $12.1M, vs. Street Est of $10.6M	29/02
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	29/02
Capricor Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02
Capricor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Sector Update: Health Care Stocks Ease Late Afternoon	27/02
Sector Update: Health Care Stocks Decline Tuesday Afternoon	27/02
Capricor Secures Meeting With FDA on CAP-1002 Manufacturing Plans; Shares Rise	27/02
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy	27/02
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29	22/02

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Capricor Therapeutics Inc Nasdaq

Acciones

US14070B1017

Otros idiomas

Filtros